Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
September 18, 2024– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2…Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
September 4, 2024– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided…Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
August 28, 2024NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024– Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President…Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
August 1, 2024– Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, August 1, 2024 – Immunic,…Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
July 24, 2024– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served…Immunic Appoints Jason Tardio as Chief Operating Officer and President
July 9, 2024– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current…Immunic to Participate in Industry and Scientific Conferences in June
May 28, 2024NEW YORK, May 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024– Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the…Immunic to Participate in Investor and Scientific Conferences in May
May 6, 2024NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
